Factor XIs: Are they the Knockout Round in Next Phase Antithrombotic Therapies?-Panel Discussion With Audience Question and Answer

Video Transcription

Video Summary

The discussion focused on the importance of phase two trials in drug development, particularly for anticoagulants used in knee arthroplasty studies. These trials provide quick results in healthy populations with known thrombosis risks, essential for dose determination and comparison with standards. Challenges arise in measuring the impact of factor XI inhibitors, and while partial thromboplastin time (PTT) is often used, its appropriateness is debated due to variations in patient responses. This uncertainty mirrors the transition from vitamin K antagonists to direct oral anticoagulants (DOACs), where precise measurement tools were initially lacking. The panel highlighted that understanding which anticoagulants might reduce thrombosis without increasing bleeding is crucial, especially in conditions like atrial fibrillation (AFib) and acute coronary syndromes. Emphasis was placed on patient-centered outcomes, such as reducing nuisance bleeding that affects adherence. The need for pharmacist involvement to navigate these advancements was underscored, reflecting ongoing developments in anticoagulant therapy.

Keywords

phase two trials

anticoagulants

knee arthroplasty

factor XI inhibitors

direct oral anticoagulants

patient-centered outcomes